Literature DB >> 9015071

Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling.

H C Steinert1, M Hauser, F Allemann, H Engel, T Berthold, G K von Schulthess, W Weder.   

Abstract

PURPOSE: To prospectively compare the accuracy of positron emission tomography (PET) with 2-[fluorine-18] fluoro-2-deoxy-D-glucose (FDG) with that of computed tomography (CT) in the nodal staging of non-small cell lung cancer.
MATERIALS AND METHODS: PET and contrast material-enhanced CT were performed in 47 patients suspected of having or with newly diagnosed non-small cell lung cancer. Each imaging study was evaluated separately, and nodal stations were localized according to the American Thoracic Society mapping system. Extensive lymph node sampling (599 nodes from 191 nodal stations) of the ipsi- and contralateral tracheobronchial and mediastinal nodal stations was performed at thoracotomy and/or mediastinoscopy. Imaging findings were correlated with histopathologic staging results.
RESULTS: The sensitivity of PET and CT was 89% and 57%, respectively, for the staging of N2 or N3 disease in mediastinal nodes; specificity was 99% and 94%, respectively; positive predictive value was 96% and 76%, respectively; negative predictive value was 97% and 87%, respectively; and accuracy was 96% and 85%, respectively. In assigning the correct N stage, PET was correct in 96% and CT in 79% of cases.
CONCLUSION: PET with FDG appears to be superior to CT for nodal staging of non-small cell lung cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9015071     DOI: 10.1148/radiology.202.2.9015071

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  27 in total

Review 1.  18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer.

Authors:  G Laking; P Price
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

Review 2.  Positron emission tomography (PET) in the evaluation of patients with cancer.

Authors:  H A Godwin; J H Zuger
Journal:  Trans Am Clin Climatol Assoc       Date:  1999

3.  Do we need randomised trials to evaluate diagnostic procedures? For.

Authors:  H Van Tinteren; O S Hoekstra; M Boers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-11-29       Impact factor: 9.236

4.  ¹⁸F-FDG uptake by spleen helps rapidly predict the dose level after total body irradiation in a Tibetan minipig model.

Authors:  Yu Jue Wang; Shao Jie Wu; Kun Yuan Guo; Chi Chen; Qiang Xie; Wei Wang Gu; Liang Cai; Fei Zou
Journal:  Eur Radiol       Date:  2012-05-02       Impact factor: 5.315

Review 5.  Evaluation of lymph node metastasis in lung cancer: who is the chief justice?

Authors:  Yang Xia; Bin Zhang; Hao Zhang; Wen Li; Ko-Pen Wang; Huahao Shen
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

6.  Oncologic positron emission tomography: a surgical perspective.

Authors:  Todd O Moore; Landis K Griffeth
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-01

7.  Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer.

Authors:  Anna C Pfannenberg; Philip Aschoff; Klaus Brechtel; Mark Müller; Roland Bares; Frank Paulsen; Jutta Scheiderbauer; Godehard Friedel; Claus D Claussen; Susanne M Eschmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08-01       Impact factor: 9.236

Review 8.  Lung cancer staging: clinical and radiologic perspectives.

Authors:  Sophie Chheang; Kathleen Brown
Journal:  Semin Intervent Radiol       Date:  2013-06       Impact factor: 1.513

Review 9.  Current role of positron emission tomography in thoracic oncology.

Authors:  V J Lowe; K S Naunheim
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

Review 10.  FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer.

Authors:  Wulf Siggelkow; Werner Rath; Udalrich Buell; Michael Zimny
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-14       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.